The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Syndax Pharmaceuticals Inc shares valued at $25,037 were purchased by Goldan Keith A. on Jun 14 ’24. At $20.03 per share, Goldan Keith A. acquired 1,250 shares. The insider’s holdings grew to 52,623 shares worth approximately $0.83 million following the completion of this transaction.
As published in their initiating research note from UBS on October 24, 2024, Syndax Pharmaceuticals Inc [SNDX] has been a Buy and the price target has been revised to $37. Analysts at Jefferies started covering the stock with ‘”a Buy”‘ outlook in a report released in late June. As of January 31, 2024, Scotiabank has decreased its “Sector outperform” rating to a “Sector perform” for SNDX. Earlier on December 22, 2023, Mizuho initiated its rating. Their recommendation was “a Buy” for SNDX stock.
Analyzing SNDX Stock Performance
During the last five days, there has been a surge of approximately 11.33%. Over the course of the year, Syndax Pharmaceuticals Inc shares have jumped approximately 19.67%. Shares of the company reached a 52-week high of $16.58 on 02/06/25 and a 52-week low of $12.06 on 01/14/25. A 50-day SMA is recorded $14.34, while a 200-day SMA reached $18.68. Nevertheless, trading volume fell to 4.37 million shares from 3.6 million shares the previous day.
Support And Resistance Levels for Syndax Pharmaceuticals Inc (SNDX)
According to the 24-hour chart, there is a support level at 15.43, which, if violated, would cause prices to drop to 15.05. In the upper region, resistance lies at 16.39. The next price resistance is at 16.97. RSI (Relative Strength Index) is 70.19 on the 14-day chart, showing overbought technical sentiment. Moving Average Convergence Divergence (MACD) is at 0.68, which suggests the price will decrease in the coming days. Percent R is at 20.77%, indicating bullish price movement. Stochastics %K at selling indicates that the stock is to be held.
